Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Almirall S.A. Stories

2014-01-16 12:29:52

Transaction Marks the Third Portfolio Realization for RoundTable's Fund II LAKE FOREST, Ill., Jan. 16, 2014 /PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the sale of Aqua Pharmaceuticals Holdings, Inc. ("Aqua") to Almirall S.A. ("Almirall") for up to $402.6 million in cash. The consideration includes $327.6 million of cash at closing plus up...

2013-12-17 12:25:43

Transaction Marks the Third Portfolio Realization for RoundTable's Fund II LAKE FOREST, Ill., Dec. 17, 2013 /PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has entered into a definitive agreement to sell Aqua Pharmaceuticals Holdings, Inc. ("Aqua") to Almirall S.A. ("Almirall") for up to $402.6 million in cash. The consideration includes $327.6 million of...

2013-10-02 08:29:56

- New data reinforces the efficacy and safety profile of Sativex® in Multiple Sclerosis Spasticity - LONDON, Oct. 2, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced that data from new MS spasticity studies (clinical trial data, observational study data and registries data collection) is being presented today at the 29(th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. The...

2013-09-23 08:27:51

LONDON, Sept. 23, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that agreement for a revised mutually-acceptable reimbursement price for Sativex® has been reached between Almirall S.A., GW's commercial partner in Germany, and the German National Association of Statutory Health Insurance Funds (GKV-SV). This new agreement has resulted in an increase to the previously reduced price imposed by the German authorities in March 2013 which...

2013-07-08 04:21:40

LONDON, July 8, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, is pleased to note the announcement from its partner Almirall S.A. that Sativex® is now available in Italy as a prescription medicine for use in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS)...

2012-11-28 12:26:33

BARCELONA, Spain and CAMBRIDGE, Massachusetts, November 28, 2012 /PRNewswire/ -- - Constella(R) (linaclotide) is the first and only medicine approved by the European Commission for the symptomatic treatment of moderate to severe IBS-C in adults, that improves abdominal pain/discomfort, bloating and constipation - First launches in Europe are expected in the first half of 2013 - IBS-C is a functional gastrointestinal disorder...

2011-09-29 05:55:00

BARCELONA, Spain, September 29, 2011 /PRNewswire/ -- - Linaclotide has demonstrated statistically significant improvement in abdominal pain/discomfort and global relief of IBS-C symptoms in Phase III clinical trials [1,2] - IBS-C is a debilitating disease associated with reduced quality of life and considerable socio-economic and psychological consequences [3,4] Almirall, S.A. (ALM.MC) announced today that it has submitted a Marketing Authorisation Application...